Zenflow
Medical device that provides a more effective, less invasive…
- Founded
- 2014
- Status
- Active
- Stage
- Growth
- Team size
- 18
- Location
- San Francisco, CA, USA; South San Francisco
- Category
- Medical Devices & Diagnostics
- Sector
- Medical Devices
About Zenflow
Forty million men in the US and over 500 million worldwide suffer from urinary obstruction related to benign prostatic hyperplasia (BPH). The majority of men will experience symptoms of this disease at some point in life. BPH, also known as prostate enlargement, leads to urinary straining, frequency, urgency, and sleep disruption. Despite the high prevalence and significant quality of life burden of BPH, established treatments are limited to drugs, which have limited effectiveness, and surgery, which carries a high risk of sexual side effects. The Zenflow Spring is a small implant delivered in the urologist's office in a simple procedure that provides quick and long-lasting symptom relief.
FDA clearances
1 510(k) clearance on record, 2025.
- Zenflow Spring Scope
K251140
Source: FDA 510(k) database via openFDA.
Clinical trials
6 registered trials with this company as lead sponsor, 2016 to 2026.
- Status
- Unknown (5), Not yet recruiting (1)
- Conditions
- Benign Prostatic Hyperplasia, BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
NCT02786290, NCT04987138, NCT03577236, NCT04309695, NCT03595735, NCT07538622
Source: ClinicalTrials.gov.
Securities filings
5 Form D filings on record, 2017 to 2024.
Filed as Zenflow, Inc.
Source: SEC EDGAR. Form D reports an exempt offering; it does not confirm funds raised.
Company data compiled and maintained by Healthcare Discovery.
